Tough on Ph+ CML in chronic phase. In a different way.
Ask your doctor about SCEMBLIX, a treatment that is tough on Ph+ CML in chronic phase
SCEMBLIX was shown to be more effective against Philadelphia chromosome–positive chronic myeloid leukemia (Ph+ CML) in chronic phase than the TKIs that doctors use most. In a clinical study of newly diagnosed patients, 68% of those taking SCEMBLIX achieved MMR at 48 weeks compared to 49% of those taking imatinib, TASIGNA® (nilotinib), Sprycel® (dasatinib), or Bosulif® (bosutinib).*
SCEMBLIX is a tyrosine kinase inhibitor (TKI) that is tough on Ph+ CML in chronic phase. It works differently than other TKIs that treat the disease.
*TASIGNA is a registered trademark of Novartis. Bosulif is a registered trademark of Pfizer Inc. Sprycel is a registered trademark of Bristol-Myers Squibb Company.
Interested in saving on SCEMBLIX?
Learn about resources for eligible patients who have been prescribed SCEMBLIX
Considering SCEMBLIX?
Sign up for information about the medication and the disease